Skip to main content
SpringerLink
Log in

Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status

  • Original Article
  • Published:
Brain Tumor Pathology Aims and scope Submit manuscript

Abstract

The impact of isocitrate dehydrogenase (IDH1/2) mutations on the malignant progression of gliomas was investigated by comparing the histopathological features of 53 grade II and III gliomas after recurrence according to the IDH1/2 status. We identified IDH1/2 mutations in 44.4 % (16 of 36) of astrocytic tumors and 70.6 % (12 of 17) of oligodendroglial tumors. Histopathological malignant progression was observed in 68.8 % (11 in 16) and 55 % (11 in 20) of astrocytic tumors with and without IDH1/2 mutations, respectively. There were 8 secondary glioblastomas (GBM) that had progressed from 5 diffuse astrocytomas (DA) and 3 anaplastic astrocytomas (AA) with IDH1/2 mutations. Seven secondary GBMs were derived from 3 DAs and 4 AAs with wild-type IDH1/2. Malignant progression was observed in 47.1 % (8 of 17) of oligodendroglial tumors. All 12 oligodendroglial tumors with IDH1/2 mutations remained as such without progressing to GBM, whereas 3 of the 5 oligodendroglial tumors without IDH1/2 mutations progressed to GBM at recurrence. In conclusion, grade II and III gliomas developed to more malignant histological types, irrespective of the IDH1/2 mutation status, and the monitoring of the IDH1/2 status could be of value to predict the development of GBM in patients with oligodendroglial tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO classification of tumours of the central nervous system, 4th edn. International Agency for Research on Cancer (IARC), Lyon

    Google Scholar 

  2. Jeuken JW, Sprenger SH, Vermeer H et al (2002) Chromosomal imbalances in primary oligodendroglial tumors and their recurrences: clues about malignant progression detected using comparative genomic hybridization. J Neurosurg 96:559–564

    Article  PubMed  Google Scholar 

  3. Ohgaki H, Kleihues P (2011) Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol 28:177–183

    Article  PubMed  CAS  Google Scholar 

  4. Miller CR, Dunham CP, Scheithauer BW, Perry A (2006) Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol 24:5419–5426

    Article  PubMed  Google Scholar 

  5. Balss J, Meyer J, Mueller W et al (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597–602

    Article  PubMed  CAS  Google Scholar 

  6. Hartmann C, Meyer J, Balss J et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118:469–474

    Article  PubMed  Google Scholar 

  7. Ichimura K, Pearson DM, Kocialkowski S et al (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11:341–347

    Article  PubMed  CAS  Google Scholar 

  8. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149–1153

    Article  PubMed  CAS  Google Scholar 

  9. Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773

    Article  PubMed  CAS  Google Scholar 

  10. Kim YH, Nobusawa S, Mittelbronn M et al (2010) Molecular classification of low-grade diffuse gliomas. Am J Pathol 177:2708–2714

    Article  PubMed  Google Scholar 

  11. Ichimura K. (2012) Molecular pathogenesis of IDH mutations in gliomas. Brain Tumor Pathol

  12. Reitman ZJ, Yan H (2010) Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 102:932–941

    Article  PubMed  CAS  Google Scholar 

  13. Capper D, Reuss D, Schittenhelm J et al (2011) Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol 121:241–252

    Article  PubMed  Google Scholar 

  14. Chaichana KL, McGirt MJ, Laterra J et al (2010) Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. J Neurosurg 112:10–17

    Article  PubMed  Google Scholar 

  15. Jaeckle KA, Decker PA, Ballman KV et al (2010) Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis. J Neurooncol 104:253–259

    Article  PubMed  Google Scholar 

  16. Lavon I, Zrihan D, Zelikovitch B et al (2007) Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas. Clin Cancer Res 13:1429–1437

    Article  PubMed  CAS  Google Scholar 

  17. McCormack BM, Miller DC, Budzilovich GN et al (1992) Treatment and survival of low-grade astrocytoma in adults—1977–1988. Neurosurgery 31:636–642 discussion 642

    Article  PubMed  CAS  Google Scholar 

  18. Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64:479–489

    PubMed  CAS  Google Scholar 

  19. Schmidt MH, Berger MS, Lamborn KR et al (2003) Repeated operations for infiltrative low-grade gliomas without intervening therapy. J Neurosurg 98:1165–1169

    Article  PubMed  Google Scholar 

  20. van den Bent MJ, Afra D, de Witte O et al (2005) Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366:985–990

    Article  PubMed  Google Scholar 

  21. Kreth FW, Faist M, Rossner R et al (1997) Supratentorial World Health Organization Grade 2 astrocytomas and oligoastrocytomas. A new pattern of prognostic factors. Cancer 79:370–379

    Article  PubMed  CAS  Google Scholar 

  22. Berger MS, Deliganis AV, Dobbins J, Keles GE (1994) The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 74:1784–1791

    Article  PubMed  CAS  Google Scholar 

  23. Claus EB, Horlacher A, Hsu L et al (2005) Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer 103:1227–1233

    Article  PubMed  Google Scholar 

  24. Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150–4154

    Article  PubMed  CAS  Google Scholar 

  25. Coons SW, Johnson PC, Scheithauer BW et al (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79:1381–1393

    Article  PubMed  CAS  Google Scholar 

  26. Labussiere M, Idbaih A, Wang XW et al (2010) All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 74:1886–1890

    Article  PubMed  CAS  Google Scholar 

  27. Giannini C, Burger PC, Berkey BA et al (2008) Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 18:360–369

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported in part by the National Cancer Center Research and Development Fund (H22-55).

Author information

Authors and Affiliations

  1. Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Makoto Ohno, Yoshitaka Narita, Yasuji Miyakita, Yoshiko Okita, Yuko Matsushita, Takamasa Kayama & Soichiro Shibui

  2. Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Akihiko Yoshida & Shintaro Fukushima

  3. Division of Brain Tumor Translational Research, National Cancer Center Research Institute, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Koichi Ichimura

Authors
  1. Makoto Ohno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshitaka Narita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasuji Miyakita
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshiko Okita
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuko Matsushita
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Akihiko Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shintaro Fukushima
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Koichi Ichimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Takamasa Kayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Soichiro Shibui
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshitaka Narita.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ohno, M., Narita, Y., Miyakita, Y. et al. Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status. Brain Tumor Pathol 29, 183–191 (2012). https://doi.org/10.1007/s10014-012-0113-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10014-012-0113-1

Keywords

Search

Navigation